Advertisement

Mechanisms of Action of Anticancer Antibiotics

  • Glynn P. Wheeler

Abstract

Perhaps at the beginningof this discussion we should give reasons why we are interested in knowing the mechanisms of action of these antibiotics. On the one hand we are interested for purely academic reasons, that is, to satisfy man’s inquisitive nature and to add to his storehouse of knowledge. This inquisitiveness leads us to ask such questions as the following:
  • Why is a material that is produced by one organism toxic to another organism?

  • Can these toxic effects be prevented or overcome?

  • Are the various toxic materials toxic for the same reason?

  • Why are some organisms not affected by these agents while other organisms are killed by them?

  • Why are some tissues or cells within an organism affected by the agents while other tissues and cells are not?

  • How do organisms become resistant to an initially toxic agent?

Keywords

Orotic Acid Purine Synthesis Purine Biosynthesis Urocanic Acid Antitumor Antibiotic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aaronson, S. 1959 Mode of action of azaserine on Gaffkya homari. J. Bact., 77, 548.PubMedGoogle Scholar
  2. Anderson, E. P., Levenberg, B., and Law, L. W. 1957 Purine biosynthesis in azaserine-sensitive and -resistant lines of the mouse plasma cell neoplasm 70429. Fed. Proc., 16, 145.Google Scholar
  3. Barclay, R. K., Garfinkel, E., and Phillipps, M. 1956 Effects of DON on incorporations of precursors into nucleic acids. Proc. Am. Assoc. Cancer Research, 2, 93.Google Scholar
  4. Bennett, L. L., Jr., Schabel, F.M.,Jr., and Skipper, H. E. 1956 Studies on the mode of action of azaserine. Arch. Biochem. and Biophys., 64, 423.Google Scholar
  5. Bentley, M., and Abrams, R. 1956 Amide-N of glutamine as source of guanine amino group. Fed. Proc., 15, 218.Google Scholar
  6. Bortle, L., and Oleson, J.J. 1955 Effect of puromycin on Tetrahymena pyriformis nutrition. Antibiotics Annual 1954–55, 770.Google Scholar
  7. Buchanan, J.M. 1958 The interference of azaserine in purine biosynthesis, in “Amino Acids and Peptides with Antimetabolic Activity,” CibaSymposium, J. and A. Churchill, Ltd., London, 75–81.Google Scholar
  8. Burchenal, J. H., Holmberg, E.A.D., Reilly, H. C., Hemphill, S., and Reppert, J. A. 1959 The effects of actinobolin on transplanted mouse leukemias. Antibiotics Annual 1958–59, 528.Google Scholar
  9. Clarke, D. A., Reilly, H. C., and Stock, C. C. 1957 A comparative study of 6-diazo-5-oxo- L-norleucine and O-diazoacetyl-L-serine on sarcoma 180. Antibiot. and Chemotherapy, 7, 653.Google Scholar
  10. Dagg, C. P., and Karnofsky, D. A. 1956 Protection against teratogenic action of azaserine and DON. Fed. Proc., 15, 238.Google Scholar
  11. Davis, J. C., and Mudd, S. 1956 Cytological effects of ultraviolet radiation and azaserine on Corynebacterium diphtheriae. J. Gen. Microbiol., 14, 527.Google Scholar
  12. DiPaolo, J. A., Moore, G. E., and Niedbala, T. F. 1957 Experimental studies with actinomycin D. Cancer Research, 17, 1127.Google Scholar
  13. Eidinoff, M. L., Knoll, J. E., Marano, B., and Cheong, L. 1958 Pyrimidine studies. I. Effect of DON (6-diazo-5-oxo-L-norleucine) on incorporation of precursors into nucleic acid pyrimidines. Cancer Research, 18, 105.Google Scholar
  14. Farber, S. 1958 Clinical and biological studies with actinomycins, in “Amino Acids and Peptides with Antimetabolic Activity,” Ciba Symposium, J. and A. Churchill Ltd., London, 138–145.Google Scholar
  15. Foley, G. E. 1956 Preliminary observations on the mechanism of action of actinomycin D in microbiologic systems. Antibiotics Annual 1955–56, 432.Google Scholar
  16. Goldthwait, D. A. 1957 Purine nucleotide biosynthesis and neoplasia, in “Henry Ford Hospital International Symposium on the Leukemias: Etiology, Pathophysiology, Treatment,” pp. 555–565. Edited by J. W. Rebuck, F. H. Bethell, and R. W. Monto, Academic Press, Inc., New York.Google Scholar
  17. Gots, J.S., and Gollub, E. G. 1956 Purine metabolism in bacteria. IV. L-Azaserine as an inhibitor. J. Bact., 72, 858.Google Scholar
  18. Greenlees, J., and LePage, G. A. 1956 Purine biosynthesis and inhibitors in ascites cell tumors. Cancer Research, 16, 808.PubMedGoogle Scholar
  19. Hedegaard, J., Thoai, N-v., and Roche, J. 1959 The influence of histidine on the biosynthesis of purines in Escherichia coli. Arch. Biochem. and Biophys., 83, 183.Google Scholar
  20. Henderson, J. F., LePage, G. A., and Mclver, F.A. 1957 Observations on the action of azaserine in mammalian tissues. Cancer Research, 17, 609.PubMedGoogle Scholar
  21. Hewitt, R.I., Gumble, A. R., Wallace, W.S., andWilliams, J. H. 1954 Experimental chemotherapy of trypanosomiasis. IV. Reversal by purines of the in vivo activity of puromycin, and an amino nucleoside analog, against Trypanosoma equiperdum. Antibiot. and Chemotherapy, 4, 1222.Google Scholar
  22. Kammen, H. O., and Hurlbert, R. B. 1959 The formation of cytidine nucleotides and RNA cytosine from orotic acid by the Novikoff tumor in vitro. Cancer Research, 19, 654.PubMedGoogle Scholar
  23. Kaplan, L., and Stock, C. C. 1954 Azaserine, an inhibitor of amino acid synthesis in Escherichia coli. Fed. Proc., 13, 239.Google Scholar
  24. Karnofsky, D. A., and Bevelander, G. 1958 Effects of DON(6-diazo-5-oxo-L-norleucine) and azaserine on the sand-dollar embryo. Proc. Soc. Exp. Biol, and Med., 97, 32.Google Scholar
  25. Langan, T. A., Jr., Kaplan, N. O., and Shuster, L. 1959 Formation of the nicotinic acid analogue of diphosphopyridine nucleotide after nicotinamide administration. J. Biol. Chem., 234, 2161.Google Scholar
  26. Mascitelli-Coriandoli, E. 1959 Effects of actinomycin-C upon the pyridoxal phosphate contents of the liver. Biochem. Pharmacol., 2, 79.Google Scholar
  27. Maxwell, R. E., and Nickel, V.S. 1954 Filament formation in E. coli induced by azaserine and other antineoplastic agents. Science, 120, 270.PubMedCrossRefGoogle Scholar
  28. Maxwell, R. E., and Nickel, V.S. 1957 6-Diazo-5-oxo-L-norleucine, a new tumor “inhibitory substance. V. Microbiologic studies of mode of action. Antibiot. and Chemotherapy, 7, 81.Google Scholar
  29. Nakamura, M. 1956 Amoebicidal action of azaserine. Nature, 178, 1119.PubMedCrossRefGoogle Scholar
  30. Narrtd, S.A., Langan, T.A., Jr., Kaplan, N. O., and Goldin, A. 1959 Effect of azaserine (o-diazoacetyl-L-serine) on the pyridine nucleotide levels of mouse liver. Nature, 183, 1674.CrossRefGoogle Scholar
  31. Potter, M., and Law, L.W. 1957 Studies on a plasma-cell neoplasm of the mouse. I. Characterization of neoplasm 70429, including its sensitivity to various antimetabolites with the rapid development of resistance to azaserine, DON, and N-methylformamide. J. Nat. Cancer Inst., 18, 413.Google Scholar
  32. Preiss, J., and Handler, P. 1958 Biosynthesis of diphosphorpyridinenucleotide. II. Enzymatic aspects. J. Biol. Chem., 233, 493.Google Scholar
  33. Raven, H. M., and Hess, G. 1959 Die Wirkung der Actinomycin C und D auf Neurospora crassa. Z. fur Physiolog. Chem., 315, 70.Google Scholar
  34. Reilly, H. C. 1954 The effect of amino acids upon the antimicrobial activity of azaserine. Proc. Am. Assoc. Cancer Research, 1, No. 2, 40.Google Scholar
  35. Reilly, H. C. 1958 Some aspects of azaserine, 6-diazo-5-oxo-L-norleucine, and fl-2- thienylalanine, in “Amino Acids and Peptides with Antimetabolic Activity.” Ciba Symposium, J. and A. Churchill, Ltd., London, 62–74.Google Scholar
  36. Reilly, H. C., Cappuccino, J. G., and Harrison, D. M. 1958 Studies on mitomycin X, A tumor-inhibiting antibiotic. Proc. Am. Assoc. Cancer Research, 2, 338.Google Scholar
  37. Sekiguchi, M., and Takagi, Y. 1959 Synthesis of deoxyribonucleic acid by phage-infected Escherichia coli in the presence of mitomycin C. Nature, 183, 1134.PubMedCrossRefGoogle Scholar
  38. Shiba, S., Terawaki, A., Taguchi, T., and Kawamata, J. 1959 Selective inhibition of formation of deoxyribonucleic acid in Escherichia coli by mitomycin C. Nature, 183, 1056.PubMedCrossRefGoogle Scholar
  39. Slotnick, I. J. 1957 Studies on the mechanism of actinomycin D inhibition of Bacillus subtilis. I. Failure to demonstrate pantothenate relationship. Antibiot. and Chemotherapy, 7, 387.Google Scholar
  40. Slotnick, I.J. 1958 Studies on the mechanism of action of actinomycin D. II. Interference with ammonia assimilation and adaptive enzyme formation. Antibiot. and Chemotherapy, 8, 476.Google Scholar
  41. Srinivasan, P. R. 1959 The enzymatic synthesis of anthranilic acid from shikimic acid-5- phosphate and L-glutamine. J. Am. Chem. Soc., 81, 1772.Google Scholar
  42. Thiersch, J. B. 1957a Effect of o-diazck acetyl-L-serine on rat litter. Proc. Soc. Exp. Biol, and Med., 94, 27.Google Scholar
  43. Thiersch, J. B. 1957b Effect of 6-diazo-5-oxo-L-norleucine (DON) on the rat litter in utero. Proc. Soc. Exp. Biol, and Med., 94, 33.Google Scholar
  44. Tomisek, A. J., Kelly, H. J., and Skipper, H. E. 1956 Chromatographic studies of purine metabolism. I. The effect of azaserine on purine biosynthesis in E. coli using various C14-labeled precursors. Arch. Biochem. and Biophys., 64, 437.Google Scholar
  45. Van der Meulen, P. Y. F., and Bassham, J. A. 1959 Study of inhibition of azaserine and diazo-oxo-nor leucine (DON) on the algae Scenedesmus and Chlorella.J. Am. Chem. Soc., 81, 2233.Google Scholar

Copyright information

© Springer Science+Business Media New York 1960

Authors and Affiliations

  • Glynn P. Wheeler
    • 1
  1. 1.Southern Research InstituteBirminghamUSA

Personalised recommendations